Literature DB >> 12725534

Differentially expressed downstream genes in cells with normal or mutated p53.

Hao Xu1, M Raafat El-Gewely.   

Abstract

Mutations in p53 gene could lead to loss of function, negative complementation, or to gain-of-oncogenic functions, thus leading to the increase of tumorigenicity and invasiveness of cancer. This study focused on cancer-related p53 mutants, including A138T, C141Y, RI58L, G245C, and R248Q. Using a modified differential display technique, response profiles of plasmid-expressed wild-type as well as mutated p53, in comparison to p53-null cells, are being established. These profiles can help our understanding of p53 involvement in cancer, leading to accurate diagnosis, treatment, and prognostic analysis by: 1) comprehensive knowledge of p53 network gene expression profiles; 2) finding the most significant gene expression profiles of p53 mutants; 3) revealing genes that only respond to p53 mutants (gain of function). Our results showed significant differences in the expression patterns among p53-null. wild-type p53, and p53 mutants A138T, C141Y, R158L, G245C, and R248Q samples. We also report here the first found p53 mutant-triggered alternative splicing.

Entities:  

Mesh:

Year:  2003        PMID: 12725534     DOI: 10.3727/096504003108748456

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  4 in total

1.  PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.

Authors:  Bo Liu; Likun Li; Guang Yang; Chuandong Geng; Yong Luo; Wenhui Wu; Ganiraju C Manyam; Dimitrios Korentzelos; Sanghee Park; Zhe Tang; Cheng Wu; Zhenyang Dong; Michael Sigouros; Andrea Sboner; Himisha Beltran; Yu Chen; Paul G Corn; Michael T Tetzlaff; Patricia Troncoso; Bradley Broom; Timothy C Thompson
Journal:  Clin Cancer Res       Date:  2019-08-22       Impact factor: 12.531

2.  An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Authors:  Ramzi M Mohammad; Jack Wu; Asfar S Azmi; Amro Aboukameel; Angela Sosin; Sherwin Wu; Dajun Yang; Shaomeng Wang; Ayad M Al-Katib
Journal:  Mol Cancer       Date:  2009-12-03       Impact factor: 27.401

3.  Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.

Authors:  Bhavya Dhaka; Radhakrishnan Sabarinathan
Journal:  BMC Cancer       Date:  2021-06-05       Impact factor: 4.430

4.  Dissecting microregulation of a master regulatory network.

Authors:  Amit U Sinha; Vivek Kaimal; Jing Chen; Anil G Jegga
Journal:  BMC Genomics       Date:  2008-02-23       Impact factor: 3.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.